The Mashelkar Panel's report (which we saw in this post) has drawn the first official response. It is from the Ministry of Chemicals and Fertilizers, and it ain't pretty:
ministry strongly feels that the report should not be accepted as ‘there is a lot of criticism’ about it. It thinks that the panel, which was given a mandate to examine whether it would be Trips-compatible to limit the grant of patent for pharmaceutical substance to a new chemical entity or to a new medical entity involving one or more inventive steps, did not ‘go into the depth of anything’, in this regard.
“The (Mashelkar) panel has failed to differentiate between incremental inventions and evergreening tactics,” said a ministry official. [bold emphasis added]
Ouch!
This comment has been removed by the author.
ReplyDeleteThere seems to be no innovation in the report. Just evergreening.
ReplyDelete